

CLAIMS

1. Use of a defective recombinant adenovirus containing an inserted gen for the preparation of a pharmaceutical composition intended for the treatment of ocular pathologies.
2. Use according to claim 1, characterized in that the defective recombinant adenovirus lacks the regions of its genome which are needed for its replication in the infected cell.
3. Use according to claims 1 or 2, characterized in that the defective recombinant adenovirus is a type Ad 2 adenovirus.
4. Use according to claim 1 or 2, characterized in that the defective recombinant adenovirus is a type Ad 5 adenovirus.
5. Use according to one of claims 1 to 4, characterized in that the inserted gene comprises sequences permitting its expression in the infected cell.
6. Use according to one of claims 1 to 5, characterized in that the inserted gene codes for a protein or a protein fragment.
7. Use according to one of claims 1 to 5, characterized in that the inserted gene is an antisense sequence.
8. Use according to claim 1 for the preparation of a pharmaceutical composition intended for the treatment of hereditary pathologies such as

09986797.11301

retinitis pigmentosa.

9. Pharmaceutical composition comprising a sufficient amount of a defective recombinant adenovirus according to claim 1, in a form suitable for ocular administration.

10. Pharmaceutical composition according to claim 9, characterized in that it comprises a sufficient amount of defective recombinant adenovirus in an injectable form suitable for ocular administration.

11. Pharmaceutical composition according to claim 9, characterized in that it comprises a sufficient amount of defective recombinant adenovirus in the form of an eye lotion or ophthalmic ointment suitable for ocular administration.

12. Pharmaceutical composition according to one of claims 9 to 11, characterized in that the defective recombinant adenovirus is a defective recombinant type Ad 2 or Ad 5 adenovirus.

13. Pharmaceutical composition according to claim 12, characterized in that it comprises between 10^4 and 10^{14} pfu/ml, and preferably 10^6 to 10^{10} pfu/ml, of defective recombinant adenovirus.

09986797.11304